Last Updated: 16 Sep 2024
Executive Summary
Cyclacel Pharmaceuticals Inc. (CYCC) is a clinical-stage biopharmaceutical company developing drugs for cancer and other proliferative diseases. Despite strong analyst support, the company faces challenges with negative financial metrics and a low market capitalization of $1.99 million. The latest stock price of $1.01 falls within the 52-week range of $0.952 to $11.34.
Company Overview
Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, New Jersey, and has a fiscal year-end in December. The company's primary focus is on developing drugs for the treatment of cancer and other proliferative diseases.
Fundamental Analysis
Cyclacel Pharmaceuticals' financial performance has been weak, with negative EBITDA, EPS, and operating margin. The company's book value per share is $0.553, and it has no dividend payments or yield.
Technical Analysis
The stock price of CYCC has been volatile over the past year, trading within a wide range. The 50-day moving average is $1.399, while the 200-day moving average is $2.181. The stock is currently trading below both moving averages.
Short Term Outlook
In the short term, CYCC may face continued volatility due to its weak financial performance. The stock price could potentially move higher if the company can demonstrate progress in its drug development pipeline or secure additional funding. However, the company may also face downward pressure if it fails to meet expectations.
Long Term Outlook
The long-term outlook for CYCC is uncertain. The company's drug development pipeline has the potential to generate revenue, but it is also risky and may not succeed. If the company can successfully develop and commercialize its drugs, it could potentially generate significant returns for investors. However, if the company fails to meet expectations, the stock price could decline further.
Analyst Recommendations
Analysts have a mixed view of CYCC. One analyst has a Strong Buy rating, while another has a Buy rating. No analysts have a Hold, Sell, or Strong Sell rating. The average analyst target price is $11, which implies a significant upside potential from the current stock price.
